Linda Ingemann

Linda Ingemann is a highly experienced Principal Clinical Pharmacology Specialist at Novo Nordisk since August 2021, previously holding significant roles at Orphazyme A/S from March 2012 to August 2021, including Associate Director of Biomarkers and Assays, where responsibilities encompassed cross-indication biomarker strategy and contributions to NDA and MAA submissions. Additional roles at Orphazyme involved Project Manager for biomarkers and Senior Scientist focusing on R&D and MOA investigations. Earlier experience included positions at ALK-abelló as a Chemist and at BRIC as a research assistant and PhD student studying hypoxia in tumor development. Linda's academic credentials include a PhD in Molecular Cancer Research from Københavns Universitet, alongside an MSc in Biology from the same institution.